Trial Profile
Exploratory research on effectiveness and safety of Rituximab treatment including maintenance administration for steroid intractable autoimmune bullous diseases of the skin. Rtx-BD Trial (Rituximab of Intractable Autoimmune Bullous Disease Trial) 2
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 26 Oct 2017
Price :
$35
*
At a glance
- Drugs Rituximab (Primary)
- Indications Pemphigoid; Pemphigus
- Focus Adverse reactions; Therapeutic Use
- Acronyms Rtx-BD Trial
- 19 Oct 2017 Status changed from suspended to discontinued.
- 16 Apr 2016 Status changed from recruiting to suspended.
- 13 Nov 2014 Status changed from not yet recruiting to recruiting as reported by University Hospital Medical Information Network - Japan.